Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors
The Oncologist · 14.11.2026
DOI: 10.1093/oncolo/oyag454 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 14.11.2026. Verfasst von Rahul Winayak und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
First-line ICI-based therapies are commonplace in mRCC and frequency of irAEs is high. Although prognostication based on irAEs has been demonstrated, prediction of irAE occurrence in mRCC remains a challenge. Early identification of high-risk patients would enable personalized monitoring, earlier detection of irAEs, and more proactive toxicity management. We investigated the role of baseline blood cell count ratios to predict grade ≥2 irAEs with first-line ICI-based therapies in mRCC. Patients and Methods We used the City of Hope national database to retrospectively identify mRCC patients treated with first-line ICI-based therapies from September 2015 to September 2025. Baseline patient demographics and first-line ICI-based regimen were collected. We stratified baseline blood cell ratios: neutrophil-to-eosinophil ratio (NER), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune inflammation index (SII) using recursive partitioning and evaluated their association with occurrence of grade ≥2 irAEs.
Results
A total of 198 patients with mRCC were treated with first-line ICI-based therapy, of which 5 were excluded due to insufficient data. Of the 193 evaluable patients, the median age was 64, 100 patients (51.8%) received ICI-ICI and 93 patients (48.2%) received ICI-TKI. Grade ≥2 irAEs were observed in 57 patients (29.5%) and the most common was ALT/AST elevations in 18 patients (9.3%). All baseline blood cell ratios predicted occurrence of grade ≥2 irAEs in separate multivariable logistic regression analyses for each marker, with SII and PLR emerging as subgroup-specific risk factors in the ICI-ICI and ICI-TKI cohorts, respectively.
Conclusion
Our findings support a novel role for these baseline blood cell ratios as factors associated with grade ≥2 irAEs in mRCC. These findings are hypothesis-generating and warrant prospective validation in larger patient populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
- Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
- Instituto Nacional de Cancerologia (INCAN), Mexico City 14080, Mexico.
- Beth Israel Deaconess Medical Center, Boston, MA, USA.
- M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Zitieren
APA
Winayak, R., Makins, K., Li, X., Salgia, N. J., Moradi, A., Abreu de Goes, V., Jaime-Casas, S., Shah, K. U., Zugman, M., Barragan-Carrillo, R., Fann, J. C., Zhang, G., Mercier, B., Jun Li, Y., Castro, D. V., Ebrahimi, H., Dizman, N., Hsu, J., Tripathi, A., …, & Pal, S. K. (2026). Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors. The Oncologist. https://doi.org/10.1093/oncolo/oyag454
Vancouver
Winayak R, Makins K, Li X, Salgia NJ, Moradi A, Abreu de Goes V, et al. Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors. The Oncologist. 2026. doi:10.1093/oncolo/oyag454
BibTeX
@article{Winayak2026,
author = {Winayak, Rahul and Makins, Kaela and Li, Xiaochen and Salgia, Nicholas J and Moradi, Ali and Abreu de Goes, Vitor and Jaime-Casas, Salvador and Shah, Koral U and Zugman, Miguel and Barragan-Carrillo, Regina and Fann, Jadon C and Zhang, George and Mercier, Benjamin and Jun Li, Yu and Castro, Daniela V and Ebrahimi, Hedyeh and Dizman, Nazli and Hsu, JoAnn and Tripathi, Abhishek and Chehrazi-Raffle, Alexander and Dorff, Tanya and Pal, Sumanta Kumar},
title = {Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag454}
}
EUVIMED